MedPageToday The vaccine appeared to prompt responses to a range of H5N1 clades. An intranasal adjuvanted recombinant influenza vaccine appeared to safely prompt a robust response to a range of H5N1 clades, according to a phase I trial.
Immune responses among the three groups that received one of three doses of the adjuvanted clade 2.1 influenza A/H5 recombinant hemagglutinin glycoprotein (rH5) vaccine were improved from baseline and they were better than those in comparator groups who received an unadjuvanted vaccine or placebo, reported Justin R. Ortiz, MD, of the Center for Vaccine Development and Global Health at the University of Maryland in Baltimore, and colleagues in Nature Communicationsopens in a new tab or window.